{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:38:39Z","timestamp":1794742719068,"version":"4.9.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Menin inhibitors (MI) disrupt the binding of menin to mixed-lineage leukemia 1 (MLL1), leading to the repression of MLL1 or MLL1-fusion protein target genes, including reduced levels of HOXA9 and MEIS1 in acute myeloid leukemia (AML) with mutant NPM1 (mtNPM1) or MLL1 rearrangement (MLL1-r). Although MI are relatively well tolerated and induce clinical remissions, they are often short-lived due to the development of resistance followed by AML relapse. Through repeated shocks with the MI SNDX-50469, a precursor tool compound to revumenib, followed by recovery, we developed MI-resistant (MITR) AML MV4-11 and OCI-AML3 cells. Present studies show that compared with MI-sensitive parental cells, MITR cells exhibit an altered epigenome, transcriptome, and proteome, without menin mutations. Through a CRISPR screen, novel druggable MI coenrichments were identified and targeted, including BRD4, SMARCA4, and CREBBP. Cotreatment with the MI and the SMARCA4\/SMARCA2 (BRG1\/BRM) inhibitor FHD-286 or the BET proteins inhibitor OTX015 (birabresib) synergistically induced in vitro lethality in MITR and MI-resistant AML cells expressing the mutant menin (M327I), as well as in patient-derived (PD) AML cells with MLL1-r or mtNPM1 that exhibited ex vivo resistance to MI. Compared with each drug alone, cotreatment with SNDX-5613 (revumenib) and FHD-286 or OTX015 and FHD-286 significantly reduced the in vivo AML burden and improved survival of the immune-depleted mice, without inducing significant toxicity, in the xenograft models of MITR and MI-resistant PD MLL1-r AML cells. These findings highlight novel, targeted, drug combinations that overcome MI resistance in AML cells with MLL1-r or mtNPM1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031486","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:06:00Z","timestamp":1771970760000},"page":"2809-2820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1\/BRM inhibitor"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-6214","authenticated-orcid":false,"given":"Warren","family":"Fiskus","sequence":"first","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-6009","authenticated-orcid":false,"given":"Christopher P.","family":"Mill","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Piel","sequence":"additional","affiliation":[{"name":"2Foghorn Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-6775","authenticated-orcid":false,"given":"Mike","family":"Collins","sequence":"additional","affiliation":[{"name":"2Foghorn Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murphy","family":"Hentemann","sequence":"additional","affiliation":[{"name":"2Foghorn Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-3522","authenticated-orcid":false,"given":"Hanxi","family":"Hou","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-3645","authenticated-orcid":false,"given":"Antrix","family":"Jain","sequence":"additional","affiliation":[{"name":"3Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-6485","authenticated-orcid":false,"given":"Anna","family":"Malovannaya","sequence":"additional","affiliation":[{"name":"3Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-2264","authenticated-orcid":false,"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5611-6014","authenticated-orcid":false,"given":"Lauren B.","family":"Flores","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Su","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil N.","family":"Bhalla","sequence":"additional","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2026060411220436200_bib1","doi-asserted-by":"crossref","first-page":"10632","DOI":"10.1073\/pnas.95.18.10632","article-title":"MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis","volume":"95","author":"Yu","year":"1998","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2026060411220436200_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1097-2765(04)00081-4","article-title":"Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus","volume":"13","author":"Hughes","year":"2004","journal-title":"Mol Cell"},{"key":"2026060411220436200_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-021-01057-7","article-title":"Structure, function and inhibition of critical protein\u2013protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins","volume":"14","author":"Li","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2026060411220436200_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem Sci"},{"issue":"36","key":"2026060411220436200_bib5","doi-asserted-by":"crossref","first-page":"31742","DOI":"10.1074\/jbc.M111.258186","article-title":"Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein","volume":"286","author":"Murai","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"2026060411220436200_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"6","key":"2026060411220436200_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.molcel.2010.05.011","article-title":"Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis","volume":"38","author":"Milne","year":"2010","journal-title":"Mol Cell"},{"issue":"22","key":"2026060411220436200_bib8","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1101\/gad.1619407","article-title":"Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis","volume":"21","author":"Argiropoulos","year":"2007","journal-title":"Genes Dev"},{"issue":"2","key":"2026060411220436200_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ccr.2009.12.040","article-title":"A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription","volume":"17","author":"Yokoyama","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"2026060411220436200_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.moh.0000160737.52349.aa","article-title":"Hox regulation of normal and leukemic hematopoietic stem cells","volume":"12","author":"Abramovich","year":"2005","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"2026060411220436200_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MOH.0000000000000245","article-title":"Deregulation of the HOXA9\/MEIS1 axis in acute leukemia","volume":"23","author":"Collins","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2026060411220436200_bib12","doi-asserted-by":"crossref","first-page":"660.e11-673.e11","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"2026060411220436200_bib13","doi-asserted-by":"crossref","first-page":"499-512.e9","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"issue":"6477","key":"2026060411220436200_bib14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"issue":"2","key":"2026060411220436200_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"key":"2026060411220436200_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exphem.2018.10.001","article-title":"Distinct pathways affected by menin versus MLL1\/MLL2 in MLL-rearranged acute myeloid leukemia","volume":"69","author":"Chen","year":"2019","journal-title":"Exp Hematol"},{"issue":"1","key":"2026060411220436200_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"2026060411220436200_bib18","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026060411220436200_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7954","key":"2026060411220436200_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"6","key":"2026060411220436200_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.2024026232","article-title":"Menin inhibitors in the treatment of acute myeloid leukemia","volume":"145","author":"Huls","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026060411220436200_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","article-title":"Revumenib: first approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"issue":"7954","key":"2026060411220436200_bib23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"20","key":"2026060411220436200_bib24","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026060411220436200_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"issue":"2","key":"2026060411220436200_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsd\u00f3ttir","year":"2013","journal-title":"Brief Bioinform"},{"issue":"3","key":"2026060411220436200_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1101\/gr.197590.115","article-title":"Models of human core transcriptional regulatory circuitries","volume":"26","author":"Saint-Andre","year":"2016","journal-title":"Genome Res"},{"issue":"43","key":"2026060411220436200_bib28","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2026060411220436200_bib29","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1101\/gr.092759.109","article-title":"Circos: an information aesthetic for comparative genomics","volume":"19","author":"Krzywinski","year":"2009","journal-title":"Genome Res"},{"issue":"3","key":"2026060411220436200_bib30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41375-020-0920-z","article-title":"The clinical impact of PTPN11 mutations in adults with acute myeloid leukemia","volume":"35","author":"Alfayez","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2026060411220436200_bib31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nbt.3235","article-title":"Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains","volume":"33","author":"Shi","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2026060411220436200_bib32","doi-asserted-by":"crossref","first-page":"564-576.e16","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"20","key":"2026060411220436200_bib33","doi-asserted-by":"crossref","first-page":"33779","DOI":"10.18632\/oncotarget.16810","article-title":"SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains","volume":"8","author":"Rzymski","year":"2017","journal-title":"Oncotarget"},{"issue":"22","key":"2026060411220436200_bib34","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/acs.jmedchem.7b00796","article-title":"GNE-781, a highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP)","volume":"60","author":"Romero","year":"2017","journal-title":"J Med Chem"},{"issue":"21","key":"2026060411220436200_bib35","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1002\/anie.201611281","article-title":"Degradation of the BAF complex factor BRD9 by heterobifunctional ligands","volume":"56","author":"Remillard","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"2026060411220436200_bib36","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"2026060411220436200_bib37","doi-asserted-by":"crossref","first-page":"123148","DOI":"10.1016\/j.lfs.2024.123148","article-title":"CDK14 is regulated by IGF2BP2 and involved in osteogenic differentiation via Wnt\/\u03b2-catenin signaling pathway in vitro","volume":"358","author":"Zhou","year":"2024","journal-title":"Life Sci"},{"issue":"24","key":"2026060411220436200_bib38","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1182\/blood-2010-05-284414","article-title":"Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists","volume":"116","author":"Mandawat","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/23\/2809\/2524612\/blood_bld-2025-031486-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/23\/2809\/2524612\/blood_bld-2025-031486-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:22:14Z","timestamp":1780586534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/23\/2809\/566838\/Overcoming-menin-inhibitor-resistance-in-AML-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":38,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031486","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,4]]},"published":{"date-parts":[[2026,6,4]]}}}